Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance
Mandate

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

January 24, 2025 Banking and Finance

Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.

The bonds carry a floating interest rate of STIBOR 3M + 4.00% and have a tenor of three years. EQL intends to apply for admission to trading of the bonds on Nasdaq Transfer Market and the corporate bond list of Nasdaq Stockholm. The net proceeds from the issuance will be used to finance the acquisition of a portfolio with original pharmaceuticals, repayment of existing financial indebtedness and for general corporate purposes.

Vinge’s team consisted of Mikael Ståhl, Arvid Weimers, August Ahlin and Sara Jansson.

Related

Vinge advises parts of the consortium in connection with the public takeover offer for Cint

 The public takeover offer was announced by a consortium consisting of Triton Fund 6, Bolero, Patrick Comer and Brett Schnittlich. The offer values all shares in Cint at approximately SEK 1,989 million. The shares in Cint are listed on Nasdaq Stockholm, Mid Cap.
April 27, 2026

Nordea and SEB enters into a SEK 2,000,000,000 credit facility agreement

 On 22 April 2026, Nordea and SEB entered into a credit facility agreement in the aggregate amount of SEK 2,000,000,000 (with an accordion option for an additional SEK 400,000,000) with Humble Group AB (publ).
April 27, 2026

Vinge has advised Northmill in connection with its inaugural issuance of primary capital instruments (AT1)

 Vinge has advised Northmill Group AB in connection with its issuance of SEK 275 million primary capital instruments (so called “AT1 bonds”) with a floating rate interest of 3-month STIBOR + 690 basis points. The AT1 bonds are perpetual with a first call option after five years and are intended to be admitted to trading on Nasdaq Transfer Market and, subsequently, on Nasdaq Stockholm.
April 27, 2026